Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and Perrigo Company plc

Innovation in Pharmaceuticals: A Tale of Two Companies

In the ever-evolving world of pharmaceuticals, innovation is the key to staying ahead. Takeda Pharmaceutical Company Limited and Perrigo Company plc offer a fascinating contrast in their approach to research and development (R&D) spending over the past decade. From 2014 to 2023, Takeda has consistently outpaced Perrigo in R&D investment, with Takeda's spending peaking at approximately 730 billion yen in 2023, a staggering 5000% more than Perrigo's highest expenditure in the same period.

While Perrigo's R&D expenses have remained relatively stable, averaging around 160 million dollars annually, Takeda's commitment to innovation is evident in its increasing investment, reflecting a strategic focus on groundbreaking research. This disparity highlights Takeda's prioritization of long-term growth and innovation, positioning it as a leader in the pharmaceutical industry. As we look to the future, the question remains: will Perrigo ramp up its R&D efforts to compete with industry giants like Takeda?